Compounds > etidronate
Page last updated: 2024-10-26

etidronate and Breast Neoplasms

etidronate has been researched along with Breast Neoplasms in 89 studies

Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.

Breast Neoplasms: Tumors or cancer of the human BREAST.

Research Excerpts

ExcerptRelevanceReference
"The aim of this multicenter, phase III, prospective open label clinical trial was to investigate the effect of risedronate (R) on bone mineral density (BMD) in postmenopausal, early breast cancer (BC) patients scheduled to receive anastrozole (A)."9.14Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. ( Antonopoulou, Z; Dafni, U; Gogas, H; Kalogerakos, K; Koukouras, D; Lazarou, S; Markopoulos, C; Misitzis, J; Papadiamantis, J; Polychronis, A; Sarantopoulou, A; Siasos, N; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2010)
"To evaluate the clinical therapeutic value of (188)Re-HEDP combined with pamidronate in breast cancer with bone metastasis."9.11[Clinical value of combined therapy with 188Re-HEDP and pamidronate in breast cancer with bone metastasis]. ( Chen, SX; DU, JQ; Jiang, NY; Liang, JG; Liu, XG; Lu, XP, 2005)
"With strict pain assessment criteria, 186Re-etidronate showed a response of 58% in the palliative treatment of metastatic bone pain originating from breast cancer."9.09186Re-etidronate in breast cancer patients with metastatic bone pain. ( Blijham, GH; de Klerk, JM; Han, SH; Quirijnen, JM; van Dijk, A; van het Schip, AD; van Rijk, PP; Zonneberg, BA, 1999)
"Influence of Rhenium-188-HEDP (Re-188), Rhenium-186-HEDP (Re-186) and Strontium-89 (Sr-89) on pain symptoms and bone marrow function were obtained in 44 patients (pts)."9.09[Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases]. ( Franke, WG; Hliscs, R; Koch, R; Kropp, J; Liepe, K; Runge, R, 2000)
"To calculate radiation doses of rhenium-186 ((186)Re) etidronate in painful bone metastases using quantitative bone single-photon emission computed tomography (SPECT) and to determine the threshold dose for predicting pain relief."9.09Quantitative bone single-photon emission computed tomography for prediction of pain relief in metastatic bone disease treated with rhenium-186 etidronate. ( Betman, L; Frenkel, A; Front, D; Iosilevski, G; Israel, O; Keidar, Z; Kolodny, GM; Kuten, A; Rubinov, R; Yarnitsky, D, 2000)
"Rhenium-188 hydroxyethylidene diphosphonate (Re-188 HEDP) is a new radiopharmaceutical for treatment of metastatic bone pain."9.09[Clinical experience with rhenium-188 HEDP therapy for metastatic bone pain]. ( Csernay, L; Láng, J; Pajor, L; Pávics, L; Róka, R; Séra, T; Thurzó, L, 2000)
"Therapy with rhenium-186 HEDP can be used complementarily to analgesic therapy in patients with painful, disseminated bone metastases."9.08[Pain therapy with rhenium-186 HEDP in multiple bone metastases]. ( Bender, H; Biersack, HJ; Dierke-Dzierzon, C; Grünwald, F; Mallmann, P; Palmedo, H; Reichmann, K; Schomburg, A; Schöneich, G; Zamorra, P, 1996)
"To present the current state of systemic radiopharmaceutical therapy for the palliation of pain in individuals with metastatic cancer and to evaluate the palliative effect and degree of hemotoxicity of strontium chloride 89 (89Sr) in patients with painful osteoblastic metastases primarily from prostate and breast cancer."8.79Strontium 89 therapy for the palliation of pain due to osseous metastases. ( Baxter, KG; Preston, DF; Robinson, RG; Schiefelbein, M, 1995)
"MDA-MB-231, T47D and MCF-7 breast cancer cells were treated with BP (zoledronic acid, risedronate, ibandronate, alendronate) and the pyrophosphate channel inhibitors probenecid and novobiocin."7.80Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells. ( Auriola, S; Coimbra de Sousa, S; Ebert, R; Graser, S; Hofbauer, LC; Jakob, F; Määttä, J; Meissner-Weigl, J; Mentrup, B; Rachner, TD; Zeck, S, 2014)
"The aim of this study was to assess the effect of adjuvant anastrozole, alone or associated with risedronate, on BMD and bone fracture risk in women more than 70 years old with hormone receptor-positive early breast cancer (EBC)."7.78Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer. ( Basso, U; Berton, L; Brunello, A; Coin, A; Falci, C; Manzato, E; Monfardini, S; Perissinotto, E; Pintore, G; Sergi, G; Veronese, N, 2012)
"The aim of this study was to compare pain response and hematologic toxicity between single and multiple therapies with (186)Re-HEDP under zoledronic acid in patients suffering from painful osseous metastases from prostate or breast cancer."7.75Management of metastatic bone pain with repeated doses of rhenium 186-HEDP in patients under therapy with zoledronic acid: a safe and additively effective practice. ( Baziotis, N; Limouris, GS; Zafeirakis, A; Zissimopoulos, A, 2009)
"For patients with metastatic prostate cancer, first results have shown that rhenium-186 (Re-186) hydroxyethylidene diphosphonate (HEDP) is efficient in pain palliation of disseminated bone metastases."7.70Pain palliation with rhenium-186 HEDP in breast cancer patients with disseminated bone metastases. ( Bender, H; Biersack, HJ; Carl, UM; Dierke-Dzierzon, C; Krebs, D; Palmedo, H; Risse, J, 1999)
"Twelve patients with metastatic breast cancer were studied."6.68Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer. ( Blijham, GH; de Klerk, JM; Quirijnen, JM; van Dijk, A; van het Schip, AD; van Rijk, PP; Zonnenberg, BA, 1996)
"Among patients with mild or severe osteopenia or osteoporosis treated with A + R, 12 months LS or HP BMD variations were configured regardless of age group."5.38Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial. ( Gogas, H; Koukouras, D; Markopoulos, C; Misitzis, J; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2012)
"The primary end point is breast cancer incidence, but major efforts are also being directed at minimizing any fracture risk."5.35IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. ( Cuzick, J, 2008)
"Lipid profiles in women with early breast cancer receiving anastrozole with or without risedronate were examined within an international Phase III/IV study to assess for possible treatment related changes."5.16Lipid profiles within the SABRE trial of anastrozole with and without risedronate. ( Barlow, DH; Clack, G; Eastell, R; Makris, A; Van Poznak, C, 2012)
"The aim of this multicenter, phase III, prospective open label clinical trial was to investigate the effect of risedronate (R) on bone mineral density (BMD) in postmenopausal, early breast cancer (BC) patients scheduled to receive anastrozole (A)."5.14Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. ( Antonopoulou, Z; Dafni, U; Gogas, H; Kalogerakos, K; Koukouras, D; Lazarou, S; Markopoulos, C; Misitzis, J; Papadiamantis, J; Polychronis, A; Sarantopoulou, A; Siasos, N; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2010)
"PURPOSE To investigate the management of bone health in women with early breast cancer (EBC) who were scheduled to receive anastrozole."5.14Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. ( Apffelstaedt, JP; Barlow, D; Campone, M; Clack, G; Eastell, R; Hannon, RA; Mackey, JR; Makris, A; Van Poznak, C, 2010)
"To evaluate the clinical therapeutic value of (188)Re-HEDP combined with pamidronate in breast cancer with bone metastasis."5.11[Clinical value of combined therapy with 188Re-HEDP and pamidronate in breast cancer with bone metastasis]. ( Chen, SX; DU, JQ; Jiang, NY; Liang, JG; Liu, XG; Lu, XP, 2005)
"Rhenium-188 hydroxyethylidene diphosphonate (Re-188 HEDP) is a new radiopharmaceutical for treatment of metastatic bone pain."5.09[Clinical experience with rhenium-188 HEDP therapy for metastatic bone pain]. ( Csernay, L; Láng, J; Pajor, L; Pávics, L; Róka, R; Séra, T; Thurzó, L, 2000)
"Influence of Rhenium-188-HEDP (Re-188), Rhenium-186-HEDP (Re-186) and Strontium-89 (Sr-89) on pain symptoms and bone marrow function were obtained in 44 patients (pts)."5.09[Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases]. ( Franke, WG; Hliscs, R; Koch, R; Kropp, J; Liepe, K; Runge, R, 2000)
"To calculate radiation doses of rhenium-186 ((186)Re) etidronate in painful bone metastases using quantitative bone single-photon emission computed tomography (SPECT) and to determine the threshold dose for predicting pain relief."5.09Quantitative bone single-photon emission computed tomography for prediction of pain relief in metastatic bone disease treated with rhenium-186 etidronate. ( Betman, L; Frenkel, A; Front, D; Iosilevski, G; Israel, O; Keidar, Z; Kolodny, GM; Kuten, A; Rubinov, R; Yarnitsky, D, 2000)
"With strict pain assessment criteria, 186Re-etidronate showed a response of 58% in the palliative treatment of metastatic bone pain originating from breast cancer."5.09186Re-etidronate in breast cancer patients with metastatic bone pain. ( Blijham, GH; de Klerk, JM; Han, SH; Quirijnen, JM; van Dijk, A; van het Schip, AD; van Rijk, PP; Zonneberg, BA, 1999)
"Therapy with rhenium-186 HEDP can be used complementarily to analgesic therapy in patients with painful, disseminated bone metastases."5.08[Pain therapy with rhenium-186 HEDP in multiple bone metastases]. ( Bender, H; Biersack, HJ; Dierke-Dzierzon, C; Grünwald, F; Mallmann, P; Palmedo, H; Reichmann, K; Schomburg, A; Schöneich, G; Zamorra, P, 1996)
"The aim of this study was to evaluate the efficacy of rhenium-186 hydroxyethyledine diphosphonate (Re-186 HEDP) for pain relief in patients with disseminated bone metastases primarily from prostate or breast cancer."5.08Rhenium-186 HEDP: palliative radionuclide therapy of painful bone metastases. Preliminary results. ( Biersack, HJ; Dierke-Dzierzon, C; Müller, SC; Palmedo, H; Schoeneich, G, 1997)
"Fifty-three white women, aged 36 to 55 years, with breast cancer and artificially induced menopause were stratified according to prior tamoxifen use."5.08Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. ( Balena, R; Bremond, A; Confravreux, E; Delmas, PD; Hardouin, C; Hardy, P, 1997)
"Studies of risedronate were obtained from the MEDLINE database (1966 to the present) of references using risedronate, risedronic acid, osteoporosis, and human subject as keywords."4.81Risedronate: a clinical review. ( Crandall, C, 2001)
"To present the current state of systemic radiopharmaceutical therapy for the palliation of pain in individuals with metastatic cancer and to evaluate the palliative effect and degree of hemotoxicity of strontium chloride 89 (89Sr) in patients with painful osteoblastic metastases primarily from prostate and breast cancer."4.79Strontium 89 therapy for the palliation of pain due to osseous metastases. ( Baxter, KG; Preston, DF; Robinson, RG; Schiefelbein, M, 1995)
"MDA-MB-231, T47D and MCF-7 breast cancer cells were treated with BP (zoledronic acid, risedronate, ibandronate, alendronate) and the pyrophosphate channel inhibitors probenecid and novobiocin."3.80Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells. ( Auriola, S; Coimbra de Sousa, S; Ebert, R; Graser, S; Hofbauer, LC; Jakob, F; Määttä, J; Meissner-Weigl, J; Mentrup, B; Rachner, TD; Zeck, S, 2014)
"The aim of this study was to assess the effect of adjuvant anastrozole, alone or associated with risedronate, on BMD and bone fracture risk in women more than 70 years old with hormone receptor-positive early breast cancer (EBC)."3.78Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer. ( Basso, U; Berton, L; Brunello, A; Coin, A; Falci, C; Manzato, E; Monfardini, S; Perissinotto, E; Pintore, G; Sergi, G; Veronese, N, 2012)
"The aim of this study was to compare pain response and hematologic toxicity between single and multiple therapies with (186)Re-HEDP under zoledronic acid in patients suffering from painful osseous metastases from prostate or breast cancer."3.75Management of metastatic bone pain with repeated doses of rhenium 186-HEDP in patients under therapy with zoledronic acid: a safe and additively effective practice. ( Baziotis, N; Limouris, GS; Zafeirakis, A; Zissimopoulos, A, 2009)
"Treatment with alendronate was associated with significantly greater improvements in lumbar spine BMD within one year in breast cancer survivors when compared with treatment with cyclic etidronate or calcium and vitamin D."3.73Are oral bisphosphonates effective in improving lumbar bone mineral density in breast cancer survivors with osteopenia or osteoporosis? ( Adachi, JD; Boulos, P; Brown, JP; Goldsmith, CH; Hanley, DA; Ioannidis, G; Josse, RG; Kouroukis, T; Murray, TM; Olszynski, WP; Papaioannou, A; Petrie, A; Sawka, AM; Sebaldt, RJ; Tenenhouse, A; Thabane, L, 2005)
"For patients with metastatic prostate cancer, first results have shown that rhenium-186 (Re-186) hydroxyethylidene diphosphonate (HEDP) is efficient in pain palliation of disseminated bone metastases."3.70Pain palliation with rhenium-186 HEDP in breast cancer patients with disseminated bone metastases. ( Bender, H; Biersack, HJ; Carl, UM; Dierke-Dzierzon, C; Krebs, D; Palmedo, H; Risse, J, 1999)
" When used orally, it can, as can pamidronate, reduce the skeletal complications of breast cancer such as hypercalcemia, bone fractures and bone pain."3.69Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer. ( Ashley, S; Hanson, J; Kanis, JA; McCloskey, E; Paterson, AH; Powles, TJ, 1995)
"Etidronate disodium (EHDP) therapy is often instituted emergently for treatment of hypercalcemia associated with malignancy, and a staging bone scan is part of the evaluation of the patient with extensive metastatic disease."3.68Skeletal nonvisualization in a bone scan secondary to intravenous etidronate therapy. ( Eary, JF; Hommeyer, SH; Varney, DM, 1992)
"Prostate or breast cancer patients with painful bone metastases receiving (188)Re-HEDP as a routine clinical procedure were eligible for evaluation."2.82Treatment of painful bone metastases in prostate and breast cancer patients with the therapeutic radiopharmaceutical rhenium-188-HEDP. Clinical benefit in a real-world study. ( Bloemendal, HJ; de Klerk, JM; Hendrikse, NH; Kooistra, A; Lange, R; Overbeek, F; Pasker-de Jong, PC; Rodenburg, CJ; Ter Heine, R; van den Berk, AM, 2016)
"In total, 79 patients (18 with breast cancer and 61 with prostate cancer) were treated (31 patients with 188Re-HEDP, 15 patients each with 186Re-HEDP and 153Sm-EDTMP, and 18 patients with 89Sr)."2.73A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. ( Kotzerke, J; Liepe, K, 2007)
"Our goal was to examine prevention of breast cancer-related bone loss in this cohort."2.73Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. ( Bhattacharya, R; Brufsky, A; Greenspan, SL; Lembersky, BC; Perera, S; Sereika, SM; Vogel, VG; Vujevich, KT, 2008)
"186Re-HEDP provides safe symptomatic relief of pain in prostate cancer patients."2.69Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer. ( Carpentier, P; Caty, A; Depreux, P; Kolesnikov-Gauthier, H; Sulman, C; Vennin, P, 2000)
"Twelve patients with metastatic breast cancer were studied."2.68Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer. ( Blijham, GH; de Klerk, JM; Quirijnen, JM; van Dijk, A; van het Schip, AD; van Rijk, PP; Zonnenberg, BA, 1996)
" Furthermore, the long-term use (>1 y) of bisphosphonate was more significant in lowering breast cancer risk."2.55Bisphosphonate use and the risk of breast cancer: a meta-analysis of observational studies. ( Chiu, HF; Ou, YJ; Wong, YH; Yang, CC; Yang, YH, 2017)
"The use of endocrine therapy in breast cancer represents one of the earliest molecular targeting strategies used in cancer treatment."2.46Challenges in clinical patient management. ( Aapro, MS, 2010)
"Pamidronate has been found to be effective in reducing skeletal morbidity associated with bone metastases in both multiple myeloma and breast carcinoma patients when given intravenously, but is ineffective orally in multiple myeloma patients."2.41Oral bisphosphonates: A review of clinical use in patients with bone metastases. ( Berenson, J; Hortobagyi, G; Lipton, A; Major, PP, 2000)
" These findings, coupled with the knowledge that suppression of bone resorption persists for the duration of treatment, has led to the long term use of oral doses of clodronate to decrease the incidence of complications of osteolytic bone disease."2.40Clodronate. ( Kanis, JA; McCloskey, EV, 1997)
"The skeleton is a common site of breast carcinoma metastasis; 75% of patients with breast carcinoma demonstrate bone metastases at autopsy."2.40Bisphosphonates and breast carcinoma. ( Lipton, A, 1997)
"Breast or prostate cancer patients were treated with zoledronate."1.39Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic. ( Fujimoto, Y; Muramatsu, K; Murayama, M; Nakata, E; Nomura, T; Ogane, S; Sekine, R; Shibahara, T; Shibui, T; Uchiyama, T; Watanabe, A; Yakushiji, T; Yamamoto, N, 2013)
"The modalities of recognition of breast tumors by Vγ9Vδ2 T cells in N-BP-treated animals were also examined."1.38In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger Vγ9Vδ2 T-cell antitumor cytotoxicity through ICAM-1 engagement. ( Benzaïd, I; Bonnelye, E; Clézardin, P; Mönkkönen, H; Mönkkönen, J, 2012)
"Among patients with mild or severe osteopenia or osteoporosis treated with A + R, 12 months LS or HP BMD variations were configured regardless of age group."1.38Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial. ( Gogas, H; Koukouras, D; Markopoulos, C; Misitzis, J; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2012)
"A total of 696 women with stage I-III breast cancer were included."1.36Outcome of patients with early breast cancer receiving nitrogen-containing bisphosphonates: a comparative analysis from the Metropolitan Detroit Cancer Surveillance System. ( Abrams, J; Bhargaval, A; Graff, JJ; Nahleh, Z; Nirmal, K, 2010)
"The indication for BP was prevention or treatment of osteoporosis in 11 cases and breast with bone metastases in one case."1.36[Jaw osteonecrosis induced by oral biphosphonates: 12 cases]. ( Barrier, A; Descroix, V; Goudot, P; Lescaille, G; Rigolet, A; Ruhin, B, 2010)
"33 patients (30 prostate carcinoma, 3 breast carcinoma) were treated with 150 MBq 89SrCl2 (9 patients), 1295 MBq 186Re-HEDP (12 patients) or 37 MBq/kg 153Sm-EDTMP (12 patients)."1.35Radiation safety considerations for the bone seeking radiopharmaceuticals. 89SrCl2, 186Re-HEDP and 153Sm-EDTMP. ( de Klerk, JM; Hoekstra, A; Lam, MG; van Rijk, PP; Zonnenberg, BA, 2009)
"Here, we used a mouse model of human breast cancer bone metastasis to examine the effects of risedronate and NE-10790, a phosphonocarboxylate analogue of the bisphosphonate risedronate, on osteolysis and tumor growth."1.35Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo. ( Clézardin, P; Daubiné, F; Ebetino, FH; Fournier, PG; Lundy, MW; Rogers, MJ, 2008)
"The primary end point is breast cancer incidence, but major efforts are also being directed at minimizing any fracture risk."1.35IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. ( Cuzick, J, 2008)
"Cytotoxicity of etidronic acid to breast cancer cells may complement its inhibitory effects on bone resorption at the site of bone metastasis."1.35Cytotoxicity of etidronic acid to human breast cancer cells. ( Ashayeri, E; Beyene, D; Kassa, A; Sridhar, R; Zhang, R; Zhou, Y, 2008)
"Subjects were 17 postmenopausal breast cancer patients (mean age, 63."1.34Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients. ( Douchi, T; Iwamoto, I; Kosha, S; Rai, Y; Sagara, Y; Yonehara, Y, 2007)
"Human breast cancer frequently metastasizes to the skeleton to cause osteolysis and subsequent pain, pathological fracture, and hypercalcemia."1.29Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. ( Boyce, BF; Boyce, R; Chapman, M; Mundy, GR; Sasaki, A; Story, B; Wright, KR; Yoneda, T, 1995)
" Half-life times of 186Re in three blood fractions (whole blood, plasma and plasma water) were 40."1.28Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases. ( de Klerk, JM; van Dijk, A; van het Schip, AD; van Rijk, PP; Zonnenberg, BA, 1992)

Research

Studies (89)

TimeframeStudies, this research(%)All Research%
pre-19908 (8.99)18.7374
1990's23 (25.84)18.2507
2000's37 (41.57)29.6817
2010's20 (22.47)24.3611
2020's1 (1.12)2.80

Authors

AuthorsStudies
Peng, R1
Liang, X1
Zhang, G1
Yao, Y1
Chen, Z1
Pan, X1
Wang, J1
Liu, G1
Ou, YJ1
Chiu, HF1
Wong, YH1
Yang, CC1
Yang, YH1
Nomura, T1
Shibahara, T1
Uchiyama, T1
Yamamoto, N1
Shibui, T1
Yakushiji, T1
Watanabe, A1
Muramatsu, K1
Ogane, S1
Murayama, M1
Sekine, R1
Nakata, E1
Fujimoto, Y1
Ben-Aharon, I1
Vidal, L1
Rizel, S1
Yerushalmi, R1
Shpilberg, O1
Sulkes, A1
Stemmer, SM1
Mansouri, M1
Mirzaei, SA1
Lage, H1
Mousavi, SS1
Elahian, F1
Ebert, R1
Meissner-Weigl, J1
Zeck, S1
Määttä, J1
Auriola, S1
Coimbra de Sousa, S1
Mentrup, B1
Graser, S1
Rachner, TD1
Hofbauer, LC1
Jakob, F1
Lange, R1
Overbeek, F1
de Klerk, JM6
Pasker-de Jong, PC1
van den Berk, AM1
Ter Heine, R1
Rodenburg, CJ1
Kooistra, A1
Hendrikse, NH1
Bloemendal, HJ1
van Londen, GJ3
Perera, S4
Vujevich, KT3
Sereika, SM4
Bhattacharya, R3
Greenspan, SL5
Zhou, Y1
Beyene, D1
Zhang, R1
Kassa, A1
Ashayeri, E1
Sridhar, R1
Cuzick, J1
Fournier, PG2
Daubiné, F1
Lundy, MW1
Rogers, MJ1
Ebetino, FH2
Clézardin, P3
Hines, SL1
Mincey, BA1
Sloan, JA1
Thomas, SP1
Chottiner, E1
Loprinzi, CL1
Carlson, MD1
Atherton, PJ1
Salim, M1
Perez, EA1
Lam, MG2
Hoekstra, A1
van Rijk, PP5
Zonnenberg, BA3
Bivi, N1
Romanello, M1
Harrison, R1
Clarke, I1
Hoyle, DC1
Moro, L1
Ortolani, F1
Bonetti, A1
Quadrifoglio, F1
Tell, G1
Delneri, D1
Waltman, NL1
Twiss, JJ1
Ott, CD1
Gross, GJ1
Lindsey, AM1
Moore, TE1
Berg, K1
Kupzyk, K1
Zafeirakis, A2
Zissimopoulos, A2
Baziotis, N2
Limouris, GS2
Van Poznak, C2
Hannon, RA1
Mackey, JR1
Campone, M1
Apffelstaedt, JP1
Clack, G2
Barlow, D1
Makris, A2
Eastell, R2
Markopoulos, C2
Tzoracoleftherakis, E2
Polychronis, A1
Venizelos, B2
Dafni, U1
Xepapadakis, G2
Papadiamantis, J1
Zobolas, V2
Misitzis, J2
Kalogerakos, K1
Sarantopoulou, A1
Siasos, N1
Koukouras, D2
Antonopoulou, Z1
Lazarou, S1
Gogas, H2
Stresing, V1
Aapro, MS1
Barrier, A1
Lescaille, G1
Rigolet, A1
Descroix, V1
Goudot, P1
Ruhin, B1
Vujevich, K1
Rastogi, P1
Lembersky, B1
Brufsky, A3
Vogel, V1
Nahleh, Z1
Abrams, J1
Bhargaval, A1
Nirmal, K1
Graff, JJ1
Sergi, G1
Pintore, G1
Falci, C1
Veronese, N1
Berton, L1
Perissinotto, E1
Basso, U1
Brunello, A1
Monfardini, S1
Manzato, E1
Coin, A1
Barlow, DH1
Benzaïd, I1
Mönkkönen, H1
Bonnelye, E1
Mönkkönen, J1
Hershman, D1
Narayanan, R1
Liepe, K3
Runge, R2
Kotzerke, J2
Liang, JG1
Jiang, NY1
DU, JQ1
Lu, XP1
Liu, XG1
Chen, SX1
Sawka, AM1
Ioannidis, G1
Papaioannou, A1
Thabane, L1
Olszynski, WP1
Brown, JP1
Hanley, DA1
Murray, TM1
Josse, RG1
Sebaldt, RJ1
Petrie, A1
Tenenhouse, A1
Goldsmith, CH1
Boulos, P1
Kouroukis, T1
Adachi, JD1
Verdijk, R1
Franke, HR1
Wolbers, F1
Vermes, I1
Minutoli, F1
Herberg, A1
Spadaro, P1
Restifo Pecorella, G1
Baldari, S2
Aricò, D1
Altavilla, G1
Bhattacharya, RK1
Vogel, VG2
Malden, NJ1
Pai, AY1
Yonehara, Y1
Iwamoto, I1
Kosha, S1
Rai, Y1
Sagara, Y1
Douchi, T1
Suyama, K1
Noguchi, Y1
Tanaka, T1
Yoshida, T1
Shibata, T1
Saito, Y1
Tatsuno, I1
Lembersky, BC1
Koutsikos, J2
Leondi, A2
Raisz, LG1
Robinson, RG1
Preston, DF1
Schiefelbein, M1
Baxter, KG1
Sasaki, A1
Boyce, BF1
Story, B1
Wright, KR1
Chapman, M1
Boyce, R1
Mundy, GR1
Yoneda, T1
van het Schip, AD3
van Dijk, A3
Quirijnen, JM2
Blijham, GH2
Silberstein, EB1
Palmedo, H5
Bender, H2
Schomburg, A1
Grünwald, F2
Schöneich, G1
Zamorra, P1
Reichmann, K1
Dierke-Dzierzon, C4
Mallmann, P1
Biersack, HJ5
Paterson, AH1
Kanis, JA2
Powles, TJ1
McCloskey, E1
Hanson, J1
Ashley, S1
Body, JJ1
Coleman, RE2
Piccart, M1
Delmas, PD1
Balena, R1
Confravreux, E1
Hardouin, C1
Hardy, P1
Bremond, A1
van Aswegen, A1
Roodt, A1
Marais, J1
Botha, JM1
Naudé, H1
Lötter, MG1
Goedhals, L1
Doman, MJ1
Otto, AC1
Lipton, A3
McCloskey, EV1
Schoeneich, G1
Müller, SC1
Hauswirth, AE1
Krebs, D3
Wagner, U1
Köhler, S1
Phillips, E1
Knowles, S1
Weber, E1
Shear, NH1
Han, SH1
Zonneberg, BA1
Carl, UM1
Risse, J1
Major, PP1
Berenson, J1
Hortobagyi, G1
Giannakenas, C1
Kalofonos, HP1
Apostolopoulos, DJ1
Zarakovitis, J1
Kosmas, C1
Vassilakos, PJ1
Sciuto, R2
Tofani, A1
Festa, A2
Giannarelli, D1
Pasqualoni, R2
Maini, CL2
Siberstein, EB1
Spencer, RP1
Róka, R1
Séra, T1
Pajor, L1
Thurzó, L1
Láng, J1
Csernay, L1
Pávics, L1
Israel, O1
Keidar, Z1
Rubinov, R1
Iosilevski, G1
Frenkel, A1
Kuten, A1
Betman, L1
Kolodny, GM1
Yarnitsky, D1
Front, D1
Küçük, NO1
Ibiş, E1
Aras, G1
Baltaci, S1
Ozalp, G1
Bedük, Y1
Canakci, N1
Soylu, A1
Kolesnikov-Gauthier, H1
Carpentier, P1
Depreux, P1
Vennin, P1
Caty, A1
Sulman, C1
Franke, WG1
Kropp, J1
Koch, R1
Hliscs, R1
Crandall, C1
Semprebene, A1
Rea, S1
Bergomi, S1
Reinholz, GG1
Getz, B1
Sanders, ES1
Karpeisky, MY1
Padyukova, NSh1
Mikhailov, SN1
Ingle, JN1
Spelsberg, TC1
Nakano, S1
Hasegawa, Y1
Shiomura, K1
Ibuka, K1
Fogelman, I1
Goll, C1
McKillop, JH1
Citrin, DL2
Greig, WR1
Bessent, RG1
McGinley, E1
Gordon, D1
Tofe, AJ1
Francis, MD1
Harvey, WJ1
Schuhmachers, G1
Worret, WI1
Hommeyer, SH1
Varney, DM1
Eary, JF1
Diel, IJ1
Warrell, RP1
Rubens, RD1
Kunkler, IH1
Merrick, MV1
Ryzen, E1
Martodam, RR1
Troxell, M1
Benson, A1
Paterson, A1
Shepard, K1
Hicks, R1

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Multicenter, Randomized, Phase II Study of Neoadjuvant Chemotherapy Associated or Not With Zoledronate and Atorvastatin in Triple Negative Breast Cancers - YAPPETIZER Study[NCT03358017]Phase 254 participants (Actual)Interventional2018-03-05Completed
A Multicenter, Single-arm, Phase II Study to Evaluate the Activity of Pre-operative Zoledronate in Triple Negative Breast Cancer Patients, According to p53 Level[NCT02347163]Phase 222 participants (Actual)Interventional2015-02-03Terminated (stopped due to The study stopped prematurely due to the low accrual rate)
A Phase III Randomized, Placebo-Controlled, Double-Blind Trial Of Risedronate (Actonel) For Prevention Of Bone Loss In Premenopausal Women Undergoing Chemotherapy For Primary Breast Carcinoma[NCT00054418]Phase 3216 participants (Actual)Interventional2003-03-31Completed
Randomized Control Trial of Bone Loading Exercises Versus Risedronate on Bone Health in Post-Menopausal Women[NCT02186600]Phase 3276 participants (Actual)Interventional2015-02-01Completed
A Phase III-IV, Multicenter Open Label Trial of Arimidex Alone Versus Arimidex Plus Bisphosphonates in Postmenopausal Patients With Early, Endocrine Positive Breast Cancer.[NCT00809484]220 participants (Actual)Observational2004-05-31Completed
The Prevention of Osteoporosis in Premenopausal and Newly Postmenopausal (Up to 8 Years) Women With Breast Cancer Following Chemotherapy (REBBeCA Study)[NCT00118508]87 participants (Actual)Interventional2003-05-31Completed
Impact of Neoadjuvant Chemotherapy With or Without Zometa on Occult Micrometastases and Bone Density in Women With Locally Advanced Breast Cancer[NCT00242203]Phase 2120 participants (Actual)Interventional2002-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Bone Mineral Density (BMD) at the Spine (L1-L4) Based on Randomization to Control, Risedronate, or Exercise Group.

Bone mineral density is the gold standard for diagnosis of low bone mass and osteoporosis and will be measured at the spine using Dual Energy X-ray Absorptiometry (DXA). (NCT02186600)
Timeframe: Baseline,6, and 12 months

,,
Interventiong/cm^2 (Mean)
Baseline6 Months12 Months
Control0.889.8870.885
Exercise0.886.8780.885
Risedronate0.892.9070.911

Change in Bone Strength Index of the Distal Tibia Based on Randomization to Control, Risedronate, or Exercise Group.

"Change in Bone Strength Index (BSI) of the distal tibia based on randomization to Control, Risedronate, or Exercise group.~BSI (mg2/mm4) at the 4% tibial site will be measured using peripheral quantitative computed tomography (pQCT)." (NCT02186600)
Timeframe: Baseline, 6, and 12 months

,,
Interventionmg^2/mm^4 (Mean)
Baseline6 Months12 Months
Control2098.72105.892107.2
Exercise20011987.422009.2
Risedronate1993.31997.322014.2

Change in Serum Measures of Bone Resorption (Serum NTx) Based on Randomization to Control, Risedronate, or Exercise Group.

Bone turnover is the process of removing old bone (resorption by osteoclasts) and replacing it with new bone (formation by osteoblasts). Menopause results in a brief period (~5 years) of accelerated turnover with resorption far exceeding formation. In this study, resorption will be measured by Serum NTx. (NCT02186600)
Timeframe: Baseline, 6, 12 months

,,
InterventionnanoMolar Bone Collagen Equivalents/L (Mean)
Baseline6 Months12 Months
Control13.9912.1612.36
Exercise15.0313.3613.92
Risedronate14.3110.3011.42

Reviews

15 reviews available for etidronate and Breast Neoplasms

ArticleYear
Association Use of Bisphosphonates with Risk of Breast Cancer: A Meta-Analysis.
    BioMed research international, 2020, Volume: 2020

    Topics: Adult; Aged; Bone Density Conservation Agents; Breast Neoplasms; Case-Control Studies; Diphosphonate

2020
Bisphosphonate use and the risk of breast cancer: a meta-analysis of observational studies.
    Pharmacoepidemiology and drug safety, 2017, Volume: 26, Issue:10

    Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonate

2017
Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis.
    PloS one, 2013, Volume: 8, Issue:8

    Topics: Antineoplastic Agents; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; C

2013
Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis.
    PloS one, 2013, Volume: 8, Issue:8

    Topics: Antineoplastic Agents; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; C

2013
Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis.
    PloS one, 2013, Volume: 8, Issue:8

    Topics: Antineoplastic Agents; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; C

2013
Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis.
    PloS one, 2013, Volume: 8, Issue:8

    Topics: Antineoplastic Agents; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; C

2013
Challenges in clinical patient management.
    Cancer investigation, 2010, Volume: 28 Suppl 1

    Topics: Aromatase Inhibitors; Bone Density; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Etid

2010
186Re-HEDP for metastatic bone pain in breast cancer patients.
    European journal of nuclear medicine and molecular imaging, 2004, Volume: 31 Suppl 1

    Topics: Bone Neoplasms; Breast Neoplasms; Dose-Response Relationship, Radiation; Etidronic Acid; Female; Hum

2004
Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer.
    Current oncology reports, 2004, Volume: 6, Issue:4

    Topics: Absorptiometry, Photon; Alendronate; Antineoplastic Agents; Bone Density; Bone Density Conservation

2004
Strontium 89 therapy for the palliation of pain due to osseous metastases.
    JAMA, 1995, Aug-02, Volume: 274, Issue:5

    Topics: Bone Neoplasms; Breast Neoplasms; Cost-Benefit Analysis; Drugs, Investigational; Etidronic Acid; Fem

1995
Use of bisphosphonates in cancer patients.
    Cancer treatment reviews, 1996, Volume: 22, Issue:4

    Topics: Alendronate; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etid

1996
Bisphosphonates and breast carcinoma.
    Cancer, 1997, Oct-15, Volume: 80, Issue:8 Suppl

    Topics: Bone Diseases; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcification, Physiologic; Clinic

1997
Clodronate.
    Cancer, 1997, Oct-15, Volume: 80, Issue:8 Suppl

    Topics: Bone Diseases; Bone Resorption; Breast Neoplasms; Cost-Benefit Analysis; Etidronic Acid; Female; Hum

1997
Aredia: the once-monthly infusion for the treatment of bone metastases.
    Current opinion in oncology, 1998, Volume: 10 Suppl 1

    Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic;

1998
Oral bisphosphonates: A review of clinical use in patients with bone metastases.
    Cancer, 2000, Jan-01, Volume: 88, Issue:1

    Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasm

2000
Risedronate: a clinical review.
    Archives of internal medicine, 2001, Feb-12, Volume: 161, Issue:3

    Topics: Animals; Bone and Bones; Bone Density; Breast Neoplasms; Calcium Channel Blockers; Etidronic Acid; F

2001
Hypercalcemia and bone metastases in breast cancer.
    Current opinion in oncology, 1990, Volume: 2, Issue:6

    Topics: Alendronate; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etidronic Acid; Hyper

1990
Bone metastases and breast cancer.
    Cancer treatment reviews, 1985, Volume: 12, Issue:4

    Topics: Alkaline Phosphatase; Bone and Bones; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium-Bin

1985

Trials

28 trials available for etidronate and Breast Neoplasms

ArticleYear
Treatment of painful bone metastases in prostate and breast cancer patients with the therapeutic radiopharmaceutical rhenium-188-HEDP. Clinical benefit in a real-world study.
    Nuklearmedizin. Nuclear medicine, 2016, Sep-26, Volume: 55, Issue:5

    Topics: Aged; Bone Neoplasms; Breast Neoplasms; Cancer Pain; Comorbidity; Etidronic Acid; Female; Humans; Ma

2016
Effect of risedronate on hip structural geometry: a 1-year, double-blind trial in chemotherapy-induced postmenopausal women.
    Bone, 2008, Volume: 43, Issue:2

    Topics: Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Double-Blind Method; Etidronic Aci

2008
Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Mar-01, Volume: 27, Issue:7

    Topics: Adult; Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neo

2009
The effect of weight training on bone mineral density and bone turnover in postmenopausal breast cancer survivors with bone loss: a 24-month randomized controlled trial.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2010, Volume: 21, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone

2010
The effect of risedronate on hip structural geometry in chemotherapy-induced postmenopausal women with or without use of aromatase inhibitors: a 2-year trial.
    Bone, 2010, Volume: 46, Issue:3

    Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Double-Blind

2010
Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Feb-20, Volume: 28, Issue:6

    Topics: Aged; Anastrozole; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neop

2010
Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial.
    Breast cancer research : BCR, 2010, Volume: 12, Issue:2

    Topics: Administration, Oral; Aged; Anastrozole; Aromatase Inhibitors; Arthralgia; Bone Density; Bone Densit

2010
The impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer.
    Breast cancer research and treatment, 2011, Volume: 125, Issue:2

    Topics: Adipose Tissue; Aromatase Inhibitors; Body Composition; Body Mass Index; Bone Density; Breast Neopla

2011
Lipid profiles within the SABRE trial of anastrozole with and without risedronate.
    Breast cancer research and treatment, 2012, Volume: 134, Issue:3

    Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Prot

2012
The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain.
    Journal of cancer research and clinical oncology, 2005, Volume: 131, Issue:1

    Topics: Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Bone Neoplasms; Breast Neoplasms; Etidronic Acid;

2005
[Clinical value of combined therapy with 188Re-HEDP and pamidronate in breast cancer with bone metastasis].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2005, Volume: 27, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carcinoembryonic Antigen; Comb

2005
[186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast.
    The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 2006, Volume: 50, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Ma

2006
Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial.
    The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:1

    Topics: Antineoplastic Agents; Bone Density; Bone Remodeling; Breast Neoplasms; Double-Blind Method; Etidron

2007
A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases.
    Nuclear medicine communications, 2007, Volume: 28, Issue:8

    Topics: Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Bone Marrow; Bone Neoplasms; Breast Neoplasms; Et

2007
Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jun-01, Volume: 26, Issue:16

    Topics: Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Calcium, Die

2008
Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1996, Volume: 37, Issue:2

    Topics: Alkaline Phosphatase; Bone Neoplasms; Breast Neoplasms; Carcinoembryonic Antigen; Dose-Response Rela

1996
Dosage and response in radiopharmaceutical therapy of painful osseous metastases.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1996, Volume: 37, Issue:2

    Topics: Bone Neoplasms; Breast Neoplasms; Dose-Response Relationship, Radiation; Etidronic Acid; Female; Hum

1996
[Pain therapy with rhenium-186 HEDP in multiple bone metastases].
    Nuklearmedizin. Nuclear medicine, 1996, Volume: 35, Issue:2

    Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Etidronic Acid; Female; Humans; Male; Neoplasm Met

1996
Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:3

    Topics: Adult; Antineoplastic Agents, Hormonal; Bone Density; Breast Neoplasms; Calcium Channel Blockers; Do

1997
Rhenium-186 HEDP: palliative radionuclide therapy of painful bone metastases. Preliminary results.
    Scandinavian journal of urology and nephrology, 1997, Volume: 31, Issue:5

    Topics: Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Male; Organometallic Compounds; Pa

1997
186Re-etidronate in breast cancer patients with metastatic bone pain.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1999, Volume: 40, Issue:4

    Topics: Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Organometallic Compounds; Pain, In

1999
Preliminary results of the use of Re-186-HEDP for palliation of pain in patients with metastatic bone disease.
    American journal of clinical oncology, 2000, Volume: 23, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Ma

2000
[Clinical experience with rhenium-188 HEDP therapy for metastatic bone pain].
    Orvosi hetilap, 2000, May-07, Volume: 141, Issue:19

    Topics: Alkaline Phosphatase; Analgesics; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans;

2000
Quantitative bone single-photon emission computed tomography for prediction of pain relief in metastatic bone disease treated with rhenium-186 etidronate.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:14

    Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Dose-Response Relationship, Radiation; Etidronic Acid

2000
Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2000, Volume: 41, Issue:10

    Topics: Adenocarcinoma; Aged; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Male; Middle

2000
[Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases].
    Nuklearmedizin. Nuclear medicine, 2000, Volume: 39, Issue:6

    Topics: Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Leukocyte Count; Male; Middle Aged

2000
Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients.
    Breast cancer research and treatment, 2001, Volume: 66, Issue:2

    Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Etidronic Acid; Female; Humans

2001
Hypercalcemia and bone metastases in breast cancer.
    Current opinion in oncology, 1990, Volume: 2, Issue:6

    Topics: Alendronate; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etidronic Acid; Hyper

1990

Other Studies

47 other studies available for etidronate and Breast Neoplasms

ArticleYear
Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic.
    The Bulletin of Tokyo Dental College, 2013, Volume: 54, Issue:2

    Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial

2013
The cell cycle arrest and the anti-invasive effects of nitrogen-containing bisphosphonates are not mediated by DBF4 in breast cancer cells.
    Biochimie, 2014, Volume: 99

    Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tum

2014
Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells.
    Molecular cancer, 2014, Dec-11, Volume: 13

    Topics: Antineoplastic Agents; Apoptosis; Bone Neoplasms; Breast Neoplasms; Caspase 3; Caspase 7; Cell Line,

2014
Cytotoxicity of etidronic acid to human breast cancer cells.
    Ethnicity & disease, 2008,Spring, Volume: 18, Issue:2 Suppl 2

    Topics: Bone Density Conservation Agents; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Etidronic Acid; Fl

2008
IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole.
    Expert review of anticancer therapy, 2008, Volume: 8, Issue:9

    Topics: Adult; Aged; Anastrozole; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms;

2008
Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo.
    Cancer research, 2008, Nov-01, Volume: 68, Issue:21

    Topics: Animals; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Drug Therapy, Combinati

2008
Radiation safety considerations for the bone seeking radiopharmaceuticals. 89SrCl2, 186Re-HEDP and 153Sm-EDTMP.
    Nuklearmedizin. Nuclear medicine, 2009, Volume: 48, Issue:1

    Topics: Adult; Aged; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Male;

2009
Identification of secondary targets of N-containing bisphosphonates in mammalian cells via parallel competition analysis of the barcoded yeast deletion collection.
    Genome biology, 2009, Volume: 10, Issue:9

    Topics: Alendronate; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Cycle Proteins; Cell Division; Ce

2009
Management of metastatic bone pain with repeated doses of rhenium 186-HEDP in patients under therapy with zoledronic acid: a safe and additively effective practice.
    Cancer biotherapy & radiopharmaceuticals, 2009, Volume: 24, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Analgesics; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Etidro

2009
How do bisphosphonates inhibit bone metastasis in vivo?
    Neoplasia (New York, N.Y.), 2010, Volume: 12, Issue:7

    Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cell L

2010
[Jaw osteonecrosis induced by oral biphosphonates: 12 cases].
    Revue de stomatologie et de chirurgie maxillo-faciale, 2010, Volume: 111, Issue:4

    Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Alendronate; Autoimmu

2010
Introduction of a new semi-quantitative index with predictive implications in patients with painful osseous metastases after (186)Re-HEDP therapy.
    The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 2011, Volume: 55, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Ka

2011
Outcome of patients with early breast cancer receiving nitrogen-containing bisphosphonates: a comparative analysis from the Metropolitan Detroit Cancer Surveillance System.
    Clinical breast cancer, 2010, Dec-01, Volume: 10, Issue:6

    Topics: Aged; Alendronate; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Etidronic Aci

2010
Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer.
    Journal of bone and mineral metabolism, 2012, Volume: 30, Issue:4

    Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone De

2012
Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial.
    Journal of cancer research and clinical oncology, 2012, Volume: 138, Issue:9

    Topics: Absorptiometry, Photon; Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Bone Densit

2012
In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger Vγ9Vδ2 T-cell antitumor cytotoxicity through ICAM-1 engagement.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Nov-15, Volume: 18, Issue:22

    Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Prolife

2012
Are oral bisphosphonates effective in improving lumbar bone mineral density in breast cancer survivors with osteopenia or osteoporosis?
    Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2005, Volume: 27, Issue:8

    Topics: Aged; Alendronate; Analysis of Variance; Bone Density; Bone Density Conservation Agents; Bone Diseas

2005
Differential effects of bisphosphonates on breast cancer cell lines.
    Cancer letters, 2007, Feb-08, Volume: 246, Issue:1-2

    Topics: Alendronate; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Clodronic Acid; Cycl

2007
Oral bisphosphonate associated osteonecrosis of the jaws: three case reports.
    British dental journal, 2007, Jul-28, Volume: 203, Issue:2

    Topics: Administration, Oral; Aged; Alendronate; Anti-Bacterial Agents; Bone Density Conservation Agents; Bo

2007
Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.
    The journal of obstetrics and gynaecology research, 2007, Volume: 33, Issue:5

    Topics: Aged; Anastrozole; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neop

2007
Isoprenoid-independent pathway is involved in apoptosis induced by risedronate, a bisphosphonate, in which Bim plays a critical role in breast cancer cell line MCF-7.
    Oncology reports, 2007, Volume: 18, Issue:5

    Topics: Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Bone Density Conservation Agents; B

2007
Treatment efficacy of combined biphosphonates and 186Re-HEDP treatment in cancer patients with bone metastases.
    European journal of nuclear medicine and molecular imaging, 2008, Volume: 35, Issue:7

    Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Dipho

2008
Re-186 HEDP treatment in breast cancer patients with bone metastases.
    Journal of the National Medical Association, 2008, Volume: 100, Issue:4

    Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Dipho

2008
New diphosphonates to block bone resorption.
    The New England journal of medicine, 1980, Feb-07, Volume: 302, Issue:6

    Topics: Animals; Bone Resorption; Breast Neoplasms; Clodronic Acid; Diphosphonates; Double-Blind Method; Eti

1980
Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
    Cancer research, 1995, Aug-15, Volume: 55, Issue:16

    Topics: Animals; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cachexia; Diphosphonates; Etidronic Acid

1995
Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer.
    The Canadian journal of oncology, 1995, Volume: 5 Suppl 1

    Topics: Analgesics, Non-Narcotic; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; D

1995
Radiation dose estimates of 186Re-hydroxyethylidene diphosphonate for palliation of metastatic osseous lesions: an animal model study.
    Nuclear medicine communications, 1997, Volume: 18, Issue:6

    Topics: Adult; Animals; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Ki

1997
[Pain therapy in multiple bone metastases in breast carcinoma with rhenium 186 HEDP].
    Zentralblatt fur Gynakologie, 1998, Volume: 120, Issue:2

    Topics: Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Middle Aged; Pain Measurement; Pal

1998
Remission of bone metastases after combined chemotherapy and radionuclide therapy with Re-186 HEDP.
    Clinical nuclear medicine, 1998, Volume: 23, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal,

1998
Skin reactions associated with bisphosphonates: a report of 3 cases and an approach to management.
    The Journal of allergy and clinical immunology, 1998, Volume: 102, Issue:4 Pt 1

    Topics: Adult; Alendronate; Antineoplastic Agents; Breast Neoplasms; Clodronic Acid; Diphosphonates; Drug Hy

1998
Pain palliation with rhenium-186 HEDP in breast cancer patients with disseminated bone metastases.
    Clinical nuclear medicine, 1999, Volume: 24, Issue:9

    Topics: Adult; Aged; Analgesics; Blood Cell Count; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female;

1999
Short- and long-term effects of 186Re-1,1-hydroxyethylidene diphosphonate in the treatment of painful bone metastases.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2000, Volume: 41, Issue:4

    Topics: Aged; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Follow-Up Studies; Humans; Male; Org

2000
Advances in our understanding of the treatment of painful bone metastasis.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2000, Volume: 41, Issue:4

    Topics: Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Male; Organometallic Compounds; Pa

2000
Quantifying leukocyte and thrombocyte suppression-recovery after Re-186 HEDP for bone metastases.
    Clinical nuclear medicine, 2000, Volume: 25, Issue:6

    Topics: Blood Platelets; Bone Marrow; Bone Neoplasms; Breast Neoplasms; Carcinoma; Etidronic Acid; Female; F

2000
Palliative analgesic effect of Re-186 HEDP in various cancer patients with bone metastases.
    Annals of nuclear medicine, 2000, Volume: 14, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Lu

2000
Drugs for prevention and treatment of postmenopausal osteoporosis.
    The Medical letter on drugs and therapeutics, 2000, Oct-16, Volume: 42, Issue:1090

    Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Resorption; Breast Neoplasms; Calciton

2000
Distinct mechanisms of bisphosphonate action between osteoblasts and breast cancer cells: identity of a potent new bisphosphonate analogue.
    Breast cancer research and treatment, 2002, Volume: 71, Issue:3

    Topics: Bone and Bones; Breast Neoplasms; Cell Differentiation; Diphosphonates; Dose-Response Relationship,

2002
[Bone scintigraphy with Tc-99m methylene diphosphonate: a comparison with ethane-hydroxy-diphosphonate (author's transl)].
    Kaku igaku. The Japanese journal of nuclear medicine, 1978, Volume: 15, Issue:4

    Topics: Bone and Bones; Breast Neoplasms; Diphosphonates; Etidronic Acid; Female; Humans; Middle Aged; Radio

1978
A clinical comparison of 2 h and 4 h bone scans obtained with 99Tc H.E.D.P.
    European journal of nuclear medicine, 1978, Volume: 3, Issue:1

    Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Male; Middle Aged; Ne

1978
Dynamic studies with 99mTc-HEDP in normal subjects and in patients with bone tumors.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1975, Volume: 16, Issue:10

    Topics: Adult; Aged; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Lung

1975
Correlation of neoplasms with incidence and localization of skeletal metastases: An analysis of 1,355 diphosphonate bone scans.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1975, Volume: 16, Issue:11

    Topics: Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Lung Neoplasms; Male; Neoplasm Met

1975
Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1992, Volume: 33, Issue:5

    Topics: Aged; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Half-Life; Humans; Male; Middle Aged

1992
[Osteoma cutis. Pathogenesis and therapeutic possibilities].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1992, Volume: 43, Issue:7

    Topics: Breast Neoplasms; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Administration Sch

1992
Skeletal nonvisualization in a bone scan secondary to intravenous etidronate therapy.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1992, Volume: 33, Issue:5

    Topics: Aged; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Carcinoma, Squamous Cell; Drug Interactions;

1992
[Current possibilities in the therapy and prevention of bone metastases in breast carcinoma?].
    Zentralblatt fur Gynakologie, 1991, Volume: 113, Issue:19

    Topics: Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Etidronic Acid; Female; Humans

1991
The value of non-staging skeletal scintigraphy in breast cancer.
    Clinical radiology, 1986, Volume: 37, Issue:6

    Topics: Actuarial Analysis; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Follow-Up Stud

1986
Intravenous etidronate in the management of malignant hypercalcemia.
    Archives of internal medicine, 1985, Volume: 145, Issue:3

    Topics: Adult; Aged; Breast Neoplasms; Calcium; Carcinoma, Squamous Cell; Etidronic Acid; Female; Head and N

1985